Related Experiment Video
Updated: May 26, 2026
08:18
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
BRAF inhibitors and melanoma
1Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA. kflaherty@partners.org
Cancer Journal (Sudbury, Mass.)
|December 14, 2011
Summary
Selective BRAF inhibitors show promise for metastatic melanoma patients with BRAF mutations, offering survival benefits. Research now focuses on overcoming resistance through combination therapies to improve durable patient responses.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Selective BRAF inhibitors are a new standard for metastatic melanoma with BRAF mutations.
- MAP kinase pathway inhibition and antitumor effects are reliably observed.
- Patient responses vary, with some durable and others short-lived.
Purpose of the Study:
- To discuss understanding de novo and acquired resistance to BRAF inhibitors.
- To explore rational combination therapy strategies for improved patient outcomes.
- To identify opportunities for combining BRAF inhibitors with other targeted therapies.
Main Methods:
- Review of current clinical evidence for BRAF inhibitors.
- Analysis of mechanisms of resistance (de novo and acquired).
- Discussion of potential combination therapies with distinct mechanisms of action.
Main Results:
- BRAF inhibitors provide an overall survival benefit for eligible patients.
- Understanding resistance mechanisms is crucial for durable responses.
- Combination therapies hold promise for enhancing treatment efficacy.
Conclusions:
- While BRAF inhibitors offer survival benefits, resistance remains a challenge.
- Developing combination therapies is essential to overcome resistance and improve outcomes.
- Further research into targeted therapies combined with BRAF inhibitors is warranted.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:30Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...